IRIS
CIMADAMORE, Alessia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.526
SA - Sud America 1.380
NA - Nord America 1.237
EU - Europa 861
AF - Africa 163
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
AN - Antartide 1
Totale 8.173
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 2.317
US - Stati Uniti d'America 1.152
BR - Brasile 1.116
CN - Cina 718
HK - Hong Kong 543
VN - Vietnam 443
RU - Federazione Russa 225
IT - Italia 212
DE - Germania 188
KR - Corea 178
AR - Argentina 104
IN - India 76
TG - Togo 67
ID - Indonesia 54
EC - Ecuador 52
MX - Messico 46
GB - Regno Unito 45
BD - Bangladesh 37
AT - Austria 32
ZA - Sudafrica 29
TR - Turchia 28
IQ - Iraq 27
CO - Colombia 26
PY - Paraguay 24
FR - Francia 23
CL - Cile 22
CA - Canada 19
PL - Polonia 19
ES - Italia 18
FI - Finlandia 16
NL - Olanda 16
JP - Giappone 14
EG - Egitto 13
VE - Venezuela 13
IE - Irlanda 12
PK - Pakistan 12
KE - Kenya 11
LT - Lituania 11
MA - Marocco 11
TN - Tunisia 11
UA - Ucraina 11
UY - Uruguay 11
UZ - Uzbekistan 11
JO - Giordania 9
PE - Perù 9
SE - Svezia 8
AE - Emirati Arabi Uniti 7
AZ - Azerbaigian 7
DZ - Algeria 5
LB - Libano 5
NP - Nepal 5
SA - Arabia Saudita 5
HN - Honduras 4
AM - Armenia 3
BH - Bahrain 3
BO - Bolivia 3
CZ - Repubblica Ceca 3
GR - Grecia 3
IL - Israele 3
IR - Iran 3
KW - Kuwait 3
KZ - Kazakistan 3
MD - Moldavia 3
OM - Oman 3
AL - Albania 2
AO - Angola 2
DO - Repubblica Dominicana 2
GT - Guatemala 2
HU - Ungheria 2
JM - Giamaica 2
LK - Sri Lanka 2
LV - Lettonia 2
NZ - Nuova Zelanda 2
PR - Porto Rico 2
PS - Palestinian Territory 2
PT - Portogallo 2
SN - Senegal 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
AD - Andorra 1
AQ - Antartide 1
AU - Australia 1
BG - Bulgaria 1
BW - Botswana 1
BY - Bielorussia 1
CD - Congo 1
CH - Svizzera 1
CR - Costa Rica 1
CW - ???statistics.table.value.countryCode.CW??? 1
DJ - Gibuti 1
ET - Etiopia 1
GM - Gambi 1
GP - Guadalupe 1
HR - Croazia 1
LA - Repubblica Popolare Democratica del Laos 1
LY - Libia 1
NA - Namibia 1
NE - Niger 1
NI - Nicaragua 1
NO - Norvegia 1
Totale 8.161
Salva come PNG Salva come JPEG
Città #
Singapore 566
Hong Kong 538
Beijing 363
Boardman 199
Hefei 183
Seoul 178
Ho Chi Minh City 164
Frankfurt am Main 134
Hanoi 103
Redondo Beach 91
Los Angeles 88
São Paulo 87
Dallas 84
Buffalo 70
Ashburn 68
Lomé 67
Ogden 59
Rio de Janeiro 39
Milan 31
Guayaquil 29
New York 25
Rome 25
Belo Horizonte 24
Brasília 23
Mexico City 23
Nuremberg 23
Porto Alegre 23
Mumbai 20
Biên Hòa 19
Curitiba 19
The Dalles 19
Hyderabad 17
Vienna 16
Da Nang 15
Campinas 14
Naples 14
Salvador 14
Codroipo 13
Ribeirão Preto 13
Warsaw 13
Brooklyn 12
Quito 12
Thái Bình 12
Tokyo 12
Goiânia 11
Haiphong 11
Johannesburg 11
Maceió 11
Munich 11
Orem 11
Atlanta 10
Chicago 10
Columbus 10
Dublin 10
Duque de Caxias 10
Franca 10
Nairobi 10
Santa Clara 10
Santo André 10
Amman 9
Ankara 9
Boston 9
Denver 9
Fortaleza 9
Montreal 9
Shanghai 9
Thái Nguyên 9
Xi'an 9
Amsterdam 8
Buenos Aires 8
Bắc Giang 8
Cabo Frio 8
Carapicuíba 8
Guarulhos 8
Helsinki 8
Hải Dương 8
Jakarta 8
Manaus 8
Montevideo 8
Tashkent 8
Tunis 8
Baku 7
Bogotá 7
Cape Town 7
Chennai 7
London 7
Ninh Bình 7
Poplar 7
Sumaré 7
Asunción 6
Hortolândia 6
La Plata 6
Lấp Vò 6
Madrid 6
Medellín 6
Nova Friburgo 6
Nova Iguaçu 6
Orta Nova 6
Aracaju 5
Baghdad 5
Totale 4.022
Salva come PNG Salva come JPEG
Nome #
News in the classification of WHO 2022 bladder tumors 135
End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer 118
SIUrO best practice recommendations to optimize BRCA 1/2 gene testing from DNA extracted from bone biopsy in mCRPC patients (BRCA Optimal Bone Biopsy Procedure: BOP) 92
Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number needed to treat analysis 92
A gender-related dichotomy in bladder cancer 69
Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer 65
Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high-grade non-muscle-invasive urothelial bladder cancer 63
Conceptual Analogies Between Multi-Scale Feeding and Feedback Cycles in Supermassive Black Hole and Cancer Environments 62
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications 61
Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems 61
Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta-analysis 61
Epigenetic modulations and lineage plasticity in advanced prostate cancer 61
Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies 59
How To Report the Minor Component of a High-grade Pattern in Radical Prostatectomy Specimens: Time To Abandon the “Tertiary” Terminology? 58
Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors 58
An update on investigational therapies that target STAT3 for the treatment of cancer 58
Histopathology of Prostate Cancer and its Precursors 57
Agent-Based Learning Model for the Obesity Paradox in RCC 57
The Prognostic Significance of Histological Subtypes in Patients with Muscle-Invasive Bladder Cancer: An Overview of the Current Literature 56
Activity of chemokines in prostate and renal tumors and their potential role as future therapeutic targets 55
Prognostic Significance of Programmed Cell Death-1, Programmed Cell Death-Ligand 1, Programmed Cell Death-Ligand 2, and Fibroblast Growth Factor Receptor 3 mRNA Expression in Bladder Cancer 55
Added Clinical Value of Whole-mount Histopathology of Radical Prostatectomy Specimens: A Collaborative Review 55
Re: Outcomes of Biopsy Grade Group 1 Prostate Cancer Diagnosis in the Danish Population 55
Biological and therapeutic implications of FGFR alterations in urothelial cancer: A systematic review from non-muscle-invasive to metastatic disease 55
Epigenetic modifications and modulators in prostate cancer 54
Targeted treatment of renal cell carcinoma 54
Are liver nested stromal epithelial tumors always low aggressive? 53
The uropathologist of the future: getting ready with intelligence for the prostate cancer tsunami 53
Frequent Telomerase Reverse Transcriptase Promoter and Fibroblast Growth Factor Receptor 3 Mutations Support the Precursor Nature of Papillary Urothelial Hyperplasia of the Urinary Bladder 53
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? 53
Re: Friederike Haidl, David Pfister, Axel Heidenreich. Re: Prostatic Artery Embolization in the Treatment of Localized Prostate Cancer: A Bicentric Prospective Proof-of-Concept Study of 12 Patients. Mordasini L, Hechelhammer L, Diener PA, et al. J Vasc Interv Radiol 2018;29:589–97. Eur Urol 2018;74:525–6: Could Morphologic Changes in Periprostatic Arteries Have an Influence on Prostatic Artery Embolization? 53
Intraductal Carcinoma of the Prostate: Pathogenesis and Molecular Perspectives 52
Treating prostate cancer by antibody-drug conjugates 52
An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer 51
An insight on novel molecular pathways in metastatic prostate cancer: A focus on ddr, msi and akt 51
Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial 50
Efficacy of Different Bacillus of Calmette-Guérin (BCG) Strains on Recurrence Rates among Intermediate/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): Single-Arm Study Systematic Review, Cumulative and Network Meta-Analysis 50
Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors 50
An update on immunotherapy in uro-oncology 50
Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer 50
Grading of Chromophobe Renal Cell Carcinoma: Do We Need It? 48
Chromophobe Renal Cell Carcinoma Aggressiveness and Immuno-oncology Therapy: How to Distinguish the Good One from the Bad One 48
Prostate cancer in 2021: Novelties in prognostic and therapeutic biomarker evaluation 48
Quick steps toward precision medicine in renal cell carcinoma 48
Narrative review of prostate cancer grading systems: Will the Gleason scores be replaced by the grade groups? 48
T1 bladder carcinoma with variant histology: pathological features and clinical significance 48
Re: Timothy D. Jones, Liang Cheng. Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Systems in Combination Provides Valuable Information for Establishing Prognostic Risk Groups. Eur Urol 2021;79:489–91 47
Emerging Molecular Technologies in Genitourinary Tumors 47
TNM staging towards a personalized approach in metastatic urothelial carcinoma: What will the future be like?-a narrative review 47
Re: George J. Netto, Mahul B. Amin, Eva M. Compérat, et al. Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.015 47
Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward 47
Follow-up of the Urethra and Management of Urethral Recurrence After Radical Cystectomy: A Systematic Review and Proposal of Management Algorithm by the European Association of Urology-Young Academic Urologists: Urothelial Carcinoma Working Group 47
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B) 47
PreImplantation Factor immunohistochemical expression correlates with prostate cancer aggressiveness 46
Patients ask and pathologists answer: ten questions around prostate cancer grading 46
Designing novel immunocombinations in metastatic renal cell carcinoma 46
Incorporating Prognostic Biomarkers into Risk Assessment Models and TNM Staging for Prostate Cancer 46
Renal Cell Carcinoma: genomic landscape and clinical implications 46
Spectrum of incipient (or precursor) lesions in the mucosa of the seminal vesicles 46
Surgical pathology of cystic renal cell carcinomas: is there an overestimation of malignancy? 46
Staging and reporting of renal cell carcinomas 46
PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What’s Now, What’s New, and What’s Coming? 46
The Role of Artificial Intelligence in the Diagnosis and Prognosis of Renal Cell Tumors 46
Re: Maria Chiara Sighinolfi, Bernardo Rocco's Words of Wisdom re: EAU Guidelines: Prostate Cancer 2019. Mottet N, van den Bergh RCN, Briers E, et al. https://uroweb.org/guideline/prostate-Cancer/. Eur Urol 2019;76:871 45
Re: Gillian Vandekerkhove, Werner J. Struss, Matti Annala, et al. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. Eur Urol 2019;75:667–75: How Does Circulating DNA Reach the Blood Stream? 45
Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis 45
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A) 45
Digital real-time microscopy of ex-vivo tissues: A novel strategy to control surgical accuracy 44
Inguinal bladder hernia with lipomatosis of the bladder wall: A potential clinical pitfall for cancer 44
The impact of lymphovascular invasion in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma: An extensive updated systematic review and meta-analysis 44
Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor? 44
Digital pathology and COVID-19 and future crises: pathologists can safely diagnose cases from home using a consumer monitor and a mini PC 43
Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: Where we stand and where we go 43
Myoid gonadal stromal tumours are characterised by recurrent chromosome-level copy number gains: molecular assessment of a multi-institutional series 43
Editorial: Emerging biomarkers in genitourinary tumors 43
Bone targeting agents in patients with metastatic prostate cancer: State of the art 43
Exploring small extracellular vesicles for precision medicine in prostate cancer 43
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer 43
Giant cell carcinoma of the urinary bladder: Clinicopathologic analysis and oncological outcomes 42
Circulating tumor cells in renal cell carcinoma: Recent findings and future challenges 42
Pathology without microscope: From a projection screen to a virtual slide 42
Lesson from the COVID-19 pandemic: pathologists need to build their confidence on working in a digital microscopy environment 42
Surgical checklist adherence across urology expertise levels impacts transurethral resection of bladder tumour quality indicators 42
Re: Theo van der Kwast, Fredrik Liedberg, Peter C. Black, et al. International Society of Urological Pathology Expert Opinion on Grading of Urothelial Carcinoma. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2021.03.017: Focus on Our Personal Recollections and Observations 42
Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer 42
Prostate cancer pathology: What has changed in the last 5 years 41
Risk Classification of Bladder Cancer by Gene Expression and Molecular Subtype 41
The most effective but largely ignored target for prostate cancer early detection and intervention 40
Tumors of the Urinary System and Male Genital Organs: 2022 World Health Organization Classification and Multidisciplinarity 40
Considerations on current and future issues related to reproducibility and accuracy in prostate cancer grading 40
Variants and Variations in Epithelial Renal Cell Tumors in Adults: The Pathologist's Point of View 40
Combining radiotherapy with immunocheckpoint inhibitors or CAR-T in Renal Cell Carcinoma 40
Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis 40
Morphologic Variants of Epithelial and Neuroendocrine Tumors of the Prostate. The Pathologist's Point of View 40
The role of obesity in renal cell carcinoma patients: Clinical-pathological implications 40
Clinicopathologic analysis of upper urinary tract carcinoma with variant histology 39
New prostate cancer targets for diagnosis, imaging, and therapy: Focus on prostate-specific membrane antigen 39
Tivozanib for the treatment of renal cell carcinoma 39
Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype 39
Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications 39
Totale 5.072
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.772
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.772
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/2023628 0 0 0 0 0 0 1 2 512 9 60 44
2023/2024411 25 9 17 10 36 24 10 22 88 112 29 29
2024/20253.489 74 226 38 51 63 162 97 106 341 449 584 1.298
2025/20264.311 502 740 1.030 924 807 308 0 0 0 0 0 0
Totale 8.839